| Harry Keith Johnson, MD | |
|
1633 Church St, Suite 160, Nashville, TN 37203-2990 | |
| (615) 329-1495 | |
| (615) 329-4450 |
| Full Name | Harry Keith Johnson |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 61 Years |
| Location | 1633 Church St, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104808641 | NPI | - | NPPES |
| 64627250 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 7208 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dialysis Clinic Inc | 4284541129 | 12 |
News Archive
Scientists at the National Cancer Institute (NCI), have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
MEDSEEK, the leading provider of enterprise-wide healthcare portal connectivity solutions, announced today that Rex Healthcare signed a multi-year agreement with MEDSEEK to design and implement a comprehensive eHealth ecoSystem, a virtual community in which patients, physicians and employees can collaborate to better manage health and more efficiently deliver healthcare, providing "the right information to the right person at the right time."
› Verified 5 days ago
| Entity Name | Dialysis Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235651829 PECOS PAC ID: 4284541129 Enrollment ID: O20170829004409 |
News Archive
Scientists at the National Cancer Institute (NCI), have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
MEDSEEK, the leading provider of enterprise-wide healthcare portal connectivity solutions, announced today that Rex Healthcare signed a multi-year agreement with MEDSEEK to design and implement a comprehensive eHealth ecoSystem, a virtual community in which patients, physicians and employees can collaborate to better manage health and more efficiently deliver healthcare, providing "the right information to the right person at the right time."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harry Keith Johnson, MD 1633 Church St, Suite 160, Nashville, TN 37203-2990 Ph: (615) 329-1495 | Harry Keith Johnson, MD 1633 Church St, Suite 160, Nashville, TN 37203-2990 Ph: (615) 329-1495 |
News Archive
Scientists at the National Cancer Institute (NCI), have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
MEDSEEK, the leading provider of enterprise-wide healthcare portal connectivity solutions, announced today that Rex Healthcare signed a multi-year agreement with MEDSEEK to design and implement a comprehensive eHealth ecoSystem, a virtual community in which patients, physicians and employees can collaborate to better manage health and more efficiently deliver healthcare, providing "the right information to the right person at the right time."
› Verified 5 days ago
Megan Desai, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Nephrology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Nephrology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |